Loading...
Loading...
In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $91.00 price target on
StrykerSYK.
In the report, Morgan Stanley noted, “The potential transaction may represent a small diversion from Stryker's recent strategy, but combining scale in orthopedics with inversion optionality creates a meaningful incentive for a deal. We see potential for up to 18% accretion and an 8% ROIC in 2017 through deal and inversion synergies.”
Stryker closed on Wednesday at $82.64.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in